[CANF] Can-Fite Biopharma Ltd

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 30.92 M

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 2.42 Change: -0.01 (-0.41%)
Ext. hours: Change: 0 (0%)

chart CANF

Refresh chart

Description: Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.

Fundamental Ratios
Shares Outstanding13.74 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow-4.27 ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week20.25 Low 52 week1.16 Last close5.15 Last change-9.01%
RSI14.02 Average true range3.86 Beta0.03 Volume40.22 K
Simple moving average 20 days-23.55% Simple moving average 50 days-51.04% Simple moving average 200 days-36.41%
Performance Data
Performance Week-20.65% Performance Month-32.67% Performance Quart-70.01% Performance Half273.19%
Performance Year293.13% Performance Year-to-date-72.75% Volatility daily5.91% Volatility weekly13.22%
Volatility monthly27.09% Volatility yearly93.85% Relative Volume163.54% Average Volume396.1 K
New High New Low

News

2020-06-04 07:14:00 | Can-Fite Concludes Successful Meeting with European Medicines Agency EMA Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer

2020-06-03 07:00:00 | Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th

2020-06-01 07:00:00 | Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update

2020-06-01 06:30:00 | Can-Fite BioPharma Ltd. to Host Earnings Call

2020-05-28 07:00:00 | Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020

2020-05-21 07:00:00 | Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office

2020-05-18 07:00:00 | Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis

2020-05-15 07:00:00 | Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms

2020-04-28 11:04:03 | Top Ranked Momentum Stocks to Buy for April 28th

2020-04-27 09:48:01 | Top Ranked Momentum Stocks to Buy for April 27th

2020-04-14 07:00:00 | Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET

2020-04-13 09:54:12 | Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics

2020-04-13 06:30:00 | Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately

2020-04-07 09:00:00 | Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson

2020-03-30 07:00:00 | Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020

2020-03-27 07:00:00 | Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update

2020-03-23 07:45:00 | Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel

2020-03-18 07:00:00 | Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment

2020-03-16 07:00:00 | Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson

2020-03-13 10:53:12 | The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals

2020-03-13 08:13:31 | Benzinga Pro's Top 5 Stocks To Watch For Fri., Mar. 13, 2020: GLD, OPK, IBIO, CPB, CANF

2020-03-13 07:54:00 | Can-Fite Surges on Study Hopes for Arthritis Drug in Coronavirus Treatment

2020-03-13 07:00:00 | Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University

2020-03-11 11:06:03 | Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

2020-03-11 07:30:00 | Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD

2020-03-06 10:45:03 | Can-Fite CANF to Explore RA Drug for Coronavirus Treatment

2020-03-05 08:08:08 | Benzinga Pro's Top 5 Stocks To Watch For Thurs., Mar. 5, 2020: ZM, MRVL, LUV, CODX, CANF

2020-03-05 08:05:44 | The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19

2020-03-05 07:00:00 | Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus

2020-03-03 07:00:00 | Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson

2020-02-27 06:00:00 | Pre-clinical Studies Demonstrate CBD’s Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement

2020-02-24 07:00:00 | Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications

2020-02-18 07:10:00 | Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter

2020-02-13 07:00:00 | Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson

2020-02-10 14:48:53 | Can-Fite BioPharma Announces Pricing of $5 Million Public Offering

2020-02-03 07:30:00 | Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis

2020-01-16 07:00:00 | Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects

2020-01-09 09:10:00 | Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million

2020-01-07 08:20:00 | Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer

2020-01-06 10:06:03 | Company News For Jan 6, 2020

2020-01-06 07:00:00 | Can-Fite CEO Issues Letter to Shareholders

2020-01-03 07:00:00 | New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss

2019-12-30 09:17:05 | CEO Of Univo Pharmaceuticals Appointed Board Member At Can-Fite

2019-12-27 10:02:03 | Company News For Dec 27, 2019

2019-12-26 07:00:00 | Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing

2019-12-09 08:15:00 | Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial

2019-12-05 07:00:00 | Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH

2019-11-29 08:20:51 | Benzinga Pro's Top 3 Stocks To Watch For Fri., Nov. 29, 2019: CANF, PCG, BBY

2019-11-29 07:00:00 | Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update

2019-11-21 07:00:00 | Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019